HARVARD BIOSCIENCE INC

For the period ended Sep 30, 2024. Filed Nov 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 8, 2024

HBIO$9.09+8.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

HARVARD BIOSCIENCE, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, in thousands, except per share data)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
Revenues	$21,970	$25,363	$69,579	$84,097
Cost of revenues	9,205	10,636	28,824	34,351
Gross profit	12,765	14,727	40,755	49,746
Sales and marketing expenses	5,518	5,732	16,817	17,888
General and administrative expenses	5,041	5,807	16,690	17,494
Research and development expenses	2,567	2,760	8,078	8,614
Amortization of intangible assets	1,334	1,361	3,998	4,138
Other operating expenses - Note 1	179	-	1,394	-
Total operating expenses	14,639	15,660	46,977	48,134
Operating (loss) income	(1,874)	(933)	(6,222)	1,612
Other income (expense):
Interest expense	(856)	(882)	(2,356)	(2,797)
Loss on pension settlement - Note 16	(1,243)	-	(1,243)	-
Gain (loss) on equity securities - Note 6	-	1,208	(1,593)	(373)
Other (expense) income, net	(518)	45	(841)	105
Total other (expense) income	(2,617)	371	(6,033)	(3,065)
Loss before income taxes	(4,491)	(562)	(12,255)	(1,453)
Income tax expense	311	677	168	144
Net loss	$(4,802)	$(1,239)	$(12,423)	$(1,597)
Loss per share:
Basic and diluted	$(0.11)	$(0.03)	$(0.29)	$(0.04)
Weighted-average common shares:
Basic and diluted	43,614	42,688	43,499	42,345

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.